Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in GERD Patients With Severe EE.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01129713|
Recruitment Status : Unknown
Verified August 2014 by Effexus Pharmaceutical.
Recruitment status was: Recruiting
First Posted : May 25, 2010
Last Update Posted : August 5, 2014
|Condition or disease||Intervention/treatment||Phase|
|Gastroesophageal Reflux Disease (GERD) Heartburn Indigestion||Drug: Secretol Drug: Nexium||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Comparison of Nexium Versus Secretol in the Healing and Controlling of Symptoms in Gastroesophageal Reflux Disease(GERD)Patients With Severe Erosive Esophagitis(EE).|
|Study Start Date :||May 2010|
|Estimated Primary Completion Date :||May 2015|
|Estimated Study Completion Date :||May 2015|
Active Comparator: Nexium
Comparing 40 mg.once daily in healing erosive esophagitis.
Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
Other Name: Esomeprazole
Active Comparator: Secretol
Comparing the efficacy of 80/80 Secretol once daily in healing erosive esophagitis.
Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
Other Name: lansoprazole/omeprazole combination
- Primary objective is to evaluate the relationship between healing and study drug allotment. [ Time Frame: 3 weeks of treatment ]The primary objective is to evaluate the relationship between healing and study drug allotment. The variables to be used are erosive esophagitis healing status after 3 weeks of treatment as assessed by EGD (upper endoscopy) comparing to base line EGD.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01129713
|Contact: Ronnie Fass, MD||520-792-1450 ext firstname.lastname@example.org|
|Contact: Marcia R. Willis, BS,CCRC||520-792-1450 ext email@example.com|
|United States, Arizona|
|Southern Arizona Veterans Health Care System||Recruiting|
|Tucson, Arizona, United States, 85723|
|Principal Investigator: Ronnie Fass, MD|
|Principal Investigator:||Ronnie Fass, MD||Southern Arizona VA Health Care System|